UroGen’s UGN-103 shows 94.5% response durability in trial
UroGen’s UGN-103 shows 94.5% response durability in trial
UroGen’s UGN-103 shows 94.5% response durability in trial
Latest in Markets
-
Jiuzi Holdings stock jumps on AI partnership deal
-
Bill Ackman built Microsoft stake in first quarter during sell-off, betting on AI and cloud growth
-
-
Earnings call transcript: The Dixie Group sees profitability surge in Q1 2026
-
Truist reiterates Buy on DexCom stock, cites growth potential
-
ZCCM-IH continues cautionary notice on ongoing negotiations
Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.